Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Gut transit time and pH shape microbiome individuality and dietary responses

Scientists reveal gut transit time and pH as key drivers of microbiome and metabolic individuality, paving the way for personalized dietary strategies.

1 Dec 2024

Can beef fit in a heart-healthy diet? Review provides new insights

A systematic review suggests unprocessed beef has minimal impact on cardiovascular health markers.

1 Dec 2024

Heart health benefits soar with regular sleep schedules, research finds

Irregular sleep patterns significantly increase the risk of major adverse cardiovascular events (MACE), with higher sleep regularity associated with reduced cardiovascular risks. This large UK Biobank study underscores the need to prioritize sleep regularity in public health and clinical guidelines.

1 Dec 2024

Men face sharper brain aging from obesity and heart risks

Obesity and cardiovascular risk factors accelerate brain volume loss, with males experiencing earlier and more significant impacts, highlighting the importance of early interventions to prevent neurodegeneration.

1 Dec 2024

How genetic traits contribute to earlier diabetes onset and metabolic challenges in South Asians

The study uncovers genetic factors driving early type 2 diabetes in South Asians, highlighting risks of insulin dependence and medication response challenges.

28 Nov 2024

Expert explores the expanding applications of GLP1 therapies

Researchers review recent advancements in glucagon-like peptide-1-based therapies.

28 Nov 2024

Understanding the pathophysiological relationship between OSA and metabolic syndrome

Cardiovascular diseases remain a leading cause of mortality globally, particularly among individuals with both obstructive sleep apnea (OSA) and metabolic syndrome (MetS).

27 Nov 2024

Study reveals protein mobility defect as a key factor in chronic diseases

Chronic diseases like type 2 diabetes and inflammatory disorders have a huge impact on humanity. They are a leading cause of disease burden and deaths around the globe, are physically and economically taxing, and the number of people with such diseases is growing.

27 Nov 2024

Younger age at type 2 diabetes diagnosis increases mortality risk

Research found that younger age at type 2 diabetes diagnosis is associated with higher risks of cardiovascular and all-cause mortality, emphasizing the need for early prevention and personalized management strategies.

27 Nov 2024

Study finds unexpected patterns in insulin needs for type 1 diabetes

Factors beyond carbohydrates have a substantial influence on blood glucose levels meaning current automated insulin delivery systems miss vital information required for glucose regulation, a new study has found.

27 Nov 2024

Insulin resistance linked to increased risk of aortic stenosis

A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development of the world's most common heart valve disease – aortic stenosis (AS).

27 Nov 2024

Cardiovascular disease risk linked to early brain decline in men

Men with cardiovascular disease risk factors, including obesity, face brain health decline a decade earlier - from their mid 50s to mid 70s - than similarly affected women who are most susceptible from their mid 60s to mid 70s, suggest the findings of a long term study, published online in the Journal of Neurology Neurosurgery & Psychiatry.

26 Nov 2024

Tirzepatide cuts diabetes risk by 90% in obese patients, study shows

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.

26 Nov 2024

Genetic factors drive early onset and complications of type 2 diabetes in British Asians

A genetic predisposition to having lower insulin production and less healthy fat distribution are major causes of early-onset type 2 diabetes in British Asian people.

26 Nov 2024

Study unlocks the secrets of beta cell regeneration

Prof. Heiko Lickert is the director of the Institute of Diabetes and Regeneration Research at Helmholtz Munich, professor at the Technical University of Munich (TUM), and member of the German Center for Diabetes Research (DZD).

26 Nov 2024

Nasal spray shows promise in combating Alzheimer's

A future treatment for Alzheimer disease may involve a nasal spray. Researchers at Università Cattolica and Fondazione Policlinico Universitario A. Gemelli IRCCS have discovered that by inhibiting the brain enzyme S-acyltransferase (zDHHC) through a nasal-spray drug, they can counteract the cognitive decline and brain damage typical of the disease.

26 Nov 2024

Atlas maps plasma proteins to transform disease diagnosis and treatment

Researchers have developed the most comprehensive atlas linking plasma proteins to diseases and traits in over 53,000 individuals, offering groundbreaking insights for precision medicine. This resource uncovers 168,100 protein-disease associations and identifies new therapeutic targets.

25 Nov 2024

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes.

25 Nov 2024

Revolutionary strategy offers hope for type 1 diabetes treatment

Regenerative medicine holds the extraordinary promise that future patients in need of new cells, tissues or organs will no longer have to rely on donors. Organ shortages and cell type mismatches will become past problems, replaced by safe, on-demand options for anyone who needs a transplant.

25 Nov 2024

New therapy from UI Health becomes the first FDA-approved treatment for brittle type 1 diabetes

A new therapy for brittle type 1 diabetes, the only treatment currently approved by the U.S. Food and Drug Administration, is available exclusively at UI Health in Chicago.

25 Nov 2024